Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccine.
López-Macías C, Torres M, Armenta-Copca B, Wacher NH, Galindo-Fraga A, Castro-Castrezana L, Colli-Domínguez AA, Cervantes-Trujano E, Rucker-Joerg IE, Lozano-Patiño F, Rivera-Alcocer JJ, Simón-Campos A, Sánchez-Campos EA, Aguirre-Rivero R, Muñiz-Carvajal AJ, Del Carpio-Orantes L, Márquez-Díaz F, Rivera-Hernández T, Torres-Flores A, Ramírez-Martínez L, la Rosa GP, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Carranza C, Juárez E, Zamudio-Meza H, Carreto-Binaghi LE, Viettri M, Romero-Rodríguez D, Palencia A, Sarfati-Mizrahi D, Sun W, Chagoya-Cortés HE, Castro-Peralta F, Palese P, Krammer F, García-Sastre A, Lozano-Dubernard B.
López-Macías C, et al. Among authors: sun w.
Sci Adv. 2025 Jun 27;11(26):eadq2887. doi: 10.1126/sciadv.adq2887. Epub 2025 Jun 27.
Sci Adv. 2025.
PMID: 40577471
Free PMC article.
Clinical Trial.